Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 8, 2015, Pages 860-863

  Fischer, Kathelijn ^a,b   Berntorp, Erik ^c,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

peak level; pharmacokinetics; prophylaxis; trough level

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8;

ARTICLE; BLOOD CLOTTING; HEMOPHILIA; HUMAN; INDIVIDUALIZATION; MINIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; PROPHYLAXIS; SEVERE HEMOPHILIA; SUBSTITUTION THERAPY; HEMOPHILIA A;

BLOOD COAGULATION FACTORS; FACTOR VIII; HEMOPHILIA A; HUMANS;

EID: 84946710809     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1552562     Document Type: Article

References (30)

1. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl: 1965; 77 (suppl): 77, 3-132
2. Nilsson I. M.; Hedner U.; Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand: 1976; 65 2 129 135
3. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol: 1969; 41 4 206 214
4. Berntorp E. History of prophylaxis. Haemophilia: 2013; 19 2 163 165
5. Berntorp E.; Astermark J.; Björkman S.; et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia: 2003; 9 01 1 4
6. Manco-Johnson M. J.; Abshire T. C.; Shapiro A. D.; et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med: 2007; 357 6 535 544
7. Gringeri A.; Lundin B.; von Mackensen S.; Mantovani L.; Mannucci P. M.; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost: 2011; 9 4 700 710
8. Valentino L. A.; Mamonov V.; Hellmann A.; et al. Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost: 2012; 10 3 359 367
9. Iorio A.; Marchesini E.; Marcucci M.; Stobart K.; Chan A. K. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev: 2011; 9 CD003429
10. Fischer K.; Steen Carlsson K.; Petrini P.; et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood: 2013; 122 7 1129 1136
11. Den Uijl I. E.; De Schepper A. M.; Camerlinck M.; Grobbee D. E.; Fischer K. Magnetic resonance imaging in teenagers and young adults with limited haemophilic arthropathy: baseline results from a prospective study. Haemophilia: 2011; 17 6 926 930
12. Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia: 2010; 16 4 597 605
13. Björkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia: 2013; 19 5 753 757
14. Carlsson M.; Berntorp E.; Björkman S.; Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol: 1993; 51 4 247 252
15. Carlsson M.; Berntorp E.; Bjorkman S.; Lethagen S.; Ljung R. CR. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia: 1997; 3 2 96 101
16. Carlsson M.; Björkman S.; Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia: 1998; 4 2 83 88
17. Nilsson I. M.; Berntorp E.; Löfqvist T.; Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med: 1992; 232 1 25 32
18. Biggs R.; MacFarlane R. G. Haemophilia and related conditions: a survey of 187 cases. Br J Haematol: 1958; 4 1 1 27
19. Den Uijl I. E.; Mauser Bunschoten E. P.; Roosendaal G.; et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia: 2011; 17 6 849 853
20. van Dijk K.; Fischer K.; van der Bom J. G.; Grobbee D. E.; van den Berg H. M. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia: 2005; 11 5 438 443
21. Ahnström J.; Berntorp E.; Lindvall K.; Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia: 2004; 10 6 689 697
22. Collins P. W.; Blanchette V. S.; Fischer K.; et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost: 2009; 7 3 413 420
23. Collins P. W.; Fischer K.; Morfini M.; Blanchette V. S.; Björkman S.; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia: 2011; 17 1 2 10
24. Astermark J.; Petrini P.; Tengborn L.; Schulman S.; Ljung R.; Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol: 1999; 105 4 1109 1113
25. Fischer K.; van der Bom J. G.; Mauser-Bunschoten E. P.; et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood: 2002; 99 7 2337 2341
26. den Uijl I.; Biesma D.; Grobbee D.; Fischer K. Outcome in moderate haemophilia. Blood Transfus: 2014; 12 01 s330 s336
27. Lindvall K.; Astermark J.; Björkman S.; et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia: 2012; 18 6 855 859
28. Oldenburg J.; Albert T. Novel products for haemostasis - current status. Haemophilia: 2014; 20 04 23 28
29. Nathwani A. C.; Reiss U. M.; Tuddenham E. G.; et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med: 2014; 371 21 1994 2004
30. Broderick C. R.; Herbert R. D.; Latimer J.; et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA: 2012; 308 14 1452 1459